Mersana Therapeutics

Mersana Therapeutics is a biopharmaceutical company based in the United States that focuses on developing innovative antibody-drug conjugates (ADCs) for cancer treatment. The company has proprietary technology platforms, Dolasynthen and Immunosynthen, which allow for customization and optimization of ADCs to address unmet medical needs. Mersana's pipeline includes both cytotoxic and immunostimulatory ADC approaches, with lead candidates such as EMI-LE and XMT-2056 currently in development.